Results 181 to 190 of about 34,611,245 (244)

Anti-inflammatory effect of Angiotensin 1-7 in white adipose tissue. [PDF]

Adipocyte
Nishida N, Sugimoto S, Miyagaki S, Cho C, Konishi M, Goda T, Yamaguchi M, Kawabe Y, Morimoto H, Kusuyama J, Okamura T, Hamaguchi M, Mori J, Nakajima H, Fukui M, Iehara T.   +15 more
europepmc   +1 more source

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Angiotensin (1-7) decreases the fibrotic process by modulating the TGF-β1/AKT pathway in rat corpus cavernosum smooth muscle cells. [PDF]

Sex Med
Xu Y, Lu Y, Liu G, Wang C, Tian S, Xiao H, Li W.   +6 more
europepmc   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Angiotensin-(1-7) protective effects in neurocognitive disorders: molecular mechanisms to therapeutic implications. [PDF]

Front Physiol
Lucas LC, Kimbark KD, Vernail VL, Silberman Y, Arnold AC.   +4 more
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Potential preventive effects of angiotensin-(1-7) on bone matrix quality in diabetic rats through modulation of the organic matrix. [PDF]

Jt Dis Relat Surg
Dalaman U, Cuneyit I, Öztürk Ş, Karagur ER, Ocak M, Yaras N, Unal M, Donmez BO.   +7 more
europepmc   +1 more source

Angiotensin-(1-7) Mitigates Progression from Acute Kidney Injury to Chronic Kidney Disease Via Renin-Angiotensin System Modulation in a Murine Model. [PDF]

Inflammation
Qiu M, Chen Y, Huang S, Ke B, Fang X, Xu C, Hua J.   +6 more
europepmc   +1 more source

WONOEP appraisal: Biomarkers and treatment strategies beyond the synapse

Epilepsia, EarlyView.
Abstract Epilepsy is a heterogeneous neurological disorder affecting more than 70 million people worldwide, posing significant challenges for clinicians due to its complex etiology, diverse manifestations, variable treatment responses, and the inability to predict seizures or disease onset reliably.
Mirte Scheper, Zining Liu, Aristea S. Galanopoulou, Gernot Hlauschek, Benjamin Sinclair, Wai Lam Leung, Stefanie Dedeurwaerdere, Elisabeth Doran, Solomon L. Moshé, David C. Henshall, Ozlem Akman, Pablo M. Casillas‐Espinosa   +11 more
wiley   +1 more source

Angiotensin-(1-7) and Central Control of Cardiometabolic Outcomes: Implications for Obesity Hypertension. [PDF]

Int J Mol Sci
Vernail VL, Lucas L, Miller AJ, Arnold AC.   +3 more
europepmc   +1 more source